Stay well informed

Investor News

We would like to inform you about the current business development of HAEMATO AG as well as about our investor relations activities.

[et_pb_section bb_built=“1″][et_pb_row][et_pb_column type=“4_4″][et_pb_text _builder_version=“3.10.1″] In the third quarter of 2018 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 69.12 million (previous year: EUR 72.5 million). In the considered period of January till September 2018 the sales amounted to € 212.8 …

[et_pb_section bb_built=“1″ _builder_version=“3.0.47″][et_pb_row _builder_version=“3.0.48″ background_size=“initial“ background_position=“top_left“ background_repeat=“repeat“][et_pb_column type=“4_4″][et_pb_text _builder_version=“3.10.1″] In the first half of 2018, the HAEMATO Group increased sales by 3.6 % year-on-year to a total of EUR 143.7 …

[et_pb_section bb_built=“1″][et_pb_row][et_pb_column type=“4_4″][et_pb_text _builder_version=“3.7″] HAEMATO AG announced today that the shareholders of the company have approved with a large majority all items on the agenda which were put to the vote by the administration at the Annual General Meeting on July 4, 2018 in Berlin. At the vote on …

[et_pb_section bb_built=“1″][et_pb_row][et_pb_column type=“4_4″][et_pb_text _builder_version=“3.4.1″] HAEMATO AG is a listed pharmaceutical company focusing on the growth markets of high-priced special pharmaceuticals from the indication areas oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In …

[et_pb_section bb_built=“1″][et_pb_row][et_pb_column type=“4_4″][et_pb_text _builder_version=“3.4.1″] HAEMATO AG is a listed pharmaceutical company with a focus on the growth markets of special pharmaceuticals, primarily in the high-priced indication areas of oncology and HIV as well as rheumatism, neurology and cardiovascular diseases. HAEMATO AG …

[et_pb_section bb_built=“1″][et_pb_row][et_pb_column type=“4_4″][et_pb_text _builder_version=“3.0.105″ background_layout=“light“ text_font=“Source Sans Pro|300|||||||“] 2017: According to the preliminary IFRS results, Haemato AG increased its sales by 5.2% to EUR 289.9 million. In 2017, HAEMATO AG, Berlin (ISIN: DE0006190705), achieved an IFRS …

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us